Skip to main content
Erschienen in: Tumor Biology 4/2016

29.10.2015 | Original Article

Insulin is an important risk factor of endometrial cancer among premenopausal women: a case-control study in China

verfasst von: Yanli Shao, Shijie Cheng, Jianqing Hou, Ying Zuo, Wei Zheng, Min Xia, Nan Mu

Erschienen in: Tumor Biology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

The aim of the article was to evaluate the important role played by insulin in the development of endometrial cancer (EC) among Chinese premenopausal women. In this study, 128 endometrial cancer patients and 294 controls who were all premenopausal were included. Baseline characteristics data were collected and serum insulin, C-peptide, sex hormone-binding globulin, C-reaction protein, interleukin-6, and tumor necrosis factor-α levels were measured. Paired t test, χ2 test, Spearman correlation coefficients, and univariate and multivariate logistic regression models were used in data analysis. Furthermore, insulin levels were categorized into quartiles, and likelihood ratio was calculated for the four categories. Blood insulin levels of the patients were significantly higher than those of the controls (P < 0.001). Factor analysis identified insulin (OR = 2.46; 95 % confidence interval (CI) = 1.55–3.91; P < 0.001) as the independent risk factor of EC. When insulin levels were categorized into quartiles, we found that insulin was positively associated with endometrial cancer risk [HR comparing extreme quartiles (HR q4-q1) = 4.44; 95 % CI = 2.59–7.62; P trend = 0.025]. After adjustment for body mass index (BMI) or waist-hip ratio (WHR), this association was attenuated, but still significant. In conclusion, insulin plays an important role in the carcinogenesis of EC among premenopausal women. Treatment targeting down-regulation of blood insulin levels seems effective in the prevention of this malignancy.
Literatur
1.
Zurück zum Zitat Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982;42:3232–9.PubMed Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982;42:3232–9.PubMed
2.
Zurück zum Zitat Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57:205–12.CrossRefPubMedPubMedCentral Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57:205–12.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the million women study. Lancet. 2005;365:1543–51.CrossRefPubMed Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the million women study. Lancet. 2005;365:1543–51.CrossRefPubMed
4.
Zurück zum Zitat Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol. 2012;125:751–7.CrossRefPubMed Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol. 2012;125:751–7.CrossRefPubMed
5.
Zurück zum Zitat Wang T, Rohan TE, Gunter MJ, Xue X, Wactawski-Wende J, Rajpathak SN, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prev. 2011;20:971–7.CrossRefPubMedPubMedCentral Wang T, Rohan TE, Gunter MJ, Xue X, Wactawski-Wende J, Rajpathak SN, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prev. 2011;20:971–7.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Dossus L, Rinaldi S, Becker S, Lukanova A, Tjonneland A, Olsen A, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer. 2010;17:1007–19.CrossRefPubMedPubMedCentral Dossus L, Rinaldi S, Becker S, Lukanova A, Tjonneland A, Olsen A, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer. 2010;17:1007–19.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Saltzman BS, Doherty JA, Hill DA, Beresford SA, Voigt LF, Chen C, et al. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am J Epidemiol. 2008;167:607–14.CrossRefPubMed Saltzman BS, Doherty JA, Hill DA, Beresford SA, Voigt LF, Chen C, et al. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am J Epidemiol. 2008;167:607–14.CrossRefPubMed
8.
Zurück zum Zitat Cote ML, Ruterbusch JJ, Ahmed Q, Bandyopadhyay S, Alosh B, Abdulfatah E, et al. Endometrial cancer in morbidly obese women: do racial disparities affect surgical or survival outcomes? Gynecol Oncol. 2014;133:38–42.CrossRefPubMedPubMedCentral Cote ML, Ruterbusch JJ, Ahmed Q, Bandyopadhyay S, Alosh B, Abdulfatah E, et al. Endometrial cancer in morbidly obese women: do racial disparities affect surgical or survival outcomes? Gynecol Oncol. 2014;133:38–42.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Cincin ZB, Iyibozkurt AC, Kuran SB, Cakmakoglu B. DNA repair gene variants in endometrial carcinoma. Med Oncol. 2012;29:2949–54.CrossRefPubMed Cincin ZB, Iyibozkurt AC, Kuran SB, Cakmakoglu B. DNA repair gene variants in endometrial carcinoma. Med Oncol. 2012;29:2949–54.CrossRefPubMed
10.
Zurück zum Zitat Canaani J, Ilan N, Back S, Gutman G, Vlodavsky I, Grisaru D. Heparanase expression increases throughout the endometrial hyperplasia-cancer sequence. Int J Gynaecol Obstet. 2008;101:166–71.CrossRefPubMed Canaani J, Ilan N, Back S, Gutman G, Vlodavsky I, Grisaru D. Heparanase expression increases throughout the endometrial hyperplasia-cancer sequence. Int J Gynaecol Obstet. 2008;101:166–71.CrossRefPubMed
11.
Zurück zum Zitat Santala S, Talvensaari-Mattila A, Soini Y, Santala M. Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma. Tumour Biol. 2015;36:953–7.CrossRefPubMed Santala S, Talvensaari-Mattila A, Soini Y, Santala M. Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma. Tumour Biol. 2015;36:953–7.CrossRefPubMed
12.
Zurück zum Zitat Dossus L, Lukanova A, Rinaldi S, Allen N, Cust AE, Becker S, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the epic cohort—a factor analysis. Am J Epidemiol. 2013;177:787–99.CrossRefPubMed Dossus L, Lukanova A, Rinaldi S, Allen N, Cust AE, Becker S, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the epic cohort—a factor analysis. Am J Epidemiol. 2013;177:787–99.CrossRefPubMed
13.
Zurück zum Zitat Iozzo P. Viewpoints on the way to the consensus session: where does insulin resistance start? The adipose tissue. Diabetes Care. 2009;32 Suppl 2:S168–73.CrossRefPubMedPubMedCentral Iozzo P. Viewpoints on the way to the consensus session: where does insulin resistance start? The adipose tissue. Diabetes Care. 2009;32 Suppl 2:S168–73.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Zamboni M, Armellini F, Cominacini L, Turcato E, Todesco T, Bissoli L, et al. Obesity and regional body-fat distribution in men: separate and joint relationships to glucose tolerance and plasma lipoproteins. Am J Clin Nutr. 1994;60:682–7.PubMed Zamboni M, Armellini F, Cominacini L, Turcato E, Todesco T, Bissoli L, et al. Obesity and regional body-fat distribution in men: separate and joint relationships to glucose tolerance and plasma lipoproteins. Am J Clin Nutr. 1994;60:682–7.PubMed
16.
Zurück zum Zitat Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988;67:460–4.CrossRefPubMed Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988;67:460–4.CrossRefPubMed
17.
Zurück zum Zitat Ogawa K, Sun C, Horii A. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade. Oncol Rep. 2005;14:1481–5.PubMed Ogawa K, Sun C, Horii A. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade. Oncol Rep. 2005;14:1481–5.PubMed
18.
Zurück zum Zitat Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K. Insulin receptor/IGF-1 receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J. 1997;327(Pt 1):209–15.CrossRefPubMedPubMedCentral Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K. Insulin receptor/IGF-1 receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J. 1997;327(Pt 1):209–15.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18.CrossRefPubMed Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18.CrossRefPubMed
20.
Zurück zum Zitat Lathi RB, Hess AP, Tulac S, Nayak NR, Conti M, Giudice LC. Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. J Clin Endocrinol Metab. 2005;90:1599–606.CrossRefPubMed Lathi RB, Hess AP, Tulac S, Nayak NR, Conti M, Giudice LC. Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. J Clin Endocrinol Metab. 2005;90:1599–606.CrossRefPubMed
21.
Zurück zum Zitat Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in mcf-7 breast cancer cells through differential regulation of c-myc and cyclin d1. Mol Cell Endocrinol. 2005;229:161–73.CrossRefPubMed Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in mcf-7 breast cancer cells through differential regulation of c-myc and cyclin d1. Mol Cell Endocrinol. 2005;229:161–73.CrossRefPubMed
22.
Zurück zum Zitat Friedenreich CM, Langley AR, Speidel TP, Lau DC, Courneya KS, Csizmadi I, et al. Case-control study of markers of insulin resistance and endometrial cancer risk. Endocr Relat Cancer. 2012;19:785–92.CrossRefPubMedPubMedCentral Friedenreich CM, Langley AR, Speidel TP, Lau DC, Courneya KS, Csizmadi I, et al. Case-control study of markers of insulin resistance and endometrial cancer risk. Endocr Relat Cancer. 2012;19:785–92.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:921–9.CrossRefPubMedPubMedCentral Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:921–9.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Lof M, Sandin S, Hilakivi-Clarke L, Weiderpass E. Birth weight in relation to endometrial and breast cancer risks in Swedish women. Br J Cancer. 2007;96:134–6.CrossRefPubMed Lof M, Sandin S, Hilakivi-Clarke L, Weiderpass E. Birth weight in relation to endometrial and breast cancer risks in Swedish women. Br J Cancer. 2007;96:134–6.CrossRefPubMed
Metadaten
Titel
Insulin is an important risk factor of endometrial cancer among premenopausal women: a case-control study in China
verfasst von
Yanli Shao
Shijie Cheng
Jianqing Hou
Ying Zuo
Wei Zheng
Min Xia
Nan Mu
Publikationsdatum
29.10.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4229-x

Weitere Artikel der Ausgabe 4/2016

Tumor Biology 4/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.